➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Moodys
AstraZeneca
Colorcon
Express Scripts
McKesson
Harvard Business School

Last Updated: May 10, 2021

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR ENTRESTO

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

All Clinical Trials for Entresto

Trial ID Title Status Sponsor Phase Start Date Summary
NCT02636283 Use of Entresto Sacubitril/Valsartan for the Treatment of Peripheral Arterial Disease Not yet recruiting American Heart Association Phase 2 2017-03-01 This study proposes the use of Entresto (sacubitril/valsartan) to test the effects on pain free walking duration on patients with peripheral arterial disease, a condition caused by decreased blood flow to the muscles in the legs.
NCT02636283 Use of Entresto Sacubitril/Valsartan for the Treatment of Peripheral Arterial Disease Not yet recruiting University of Minnesota - Clinical and Translational Science Institute Phase 2 2017-03-01 This study proposes the use of Entresto (sacubitril/valsartan) to test the effects on pain free walking duration on patients with peripheral arterial disease, a condition caused by decreased blood flow to the muscles in the legs.
NCT02682719 ARNI in Asymptomatic Patients With Elevated Natriuretic Peptide and Elevated Left Atrial Volume Index eLEvation Recruiting Novartis Ireland Ltd Phase 2 2015-12-01 The purpose of this study is to determine whether LCZ696 (valsartan/sacubitril) is safe and has beneficial effects on the heart and blood vessels in patients with high blood pressure and/or diabetes or other risk factors for developing heart failure (elevated levels of natriuretic peptide and elevated left atrial volume index). Patients will be randomized to receive LCZ696 or valsartan (and matching placebo) for 18 months to assess the impact on left ventricular diastolic function.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Entresto

Condition Name

Condition Name for Entresto
Intervention Trials
Heart Failure 12
Hypertension 4
Diastolic Dysfunction 3
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Entresto
Intervention Trials
Heart Failure 22
Hypertension 3
Diabetes Mellitus, Type 2 3
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Entresto

Trials by Country

Trials by Country for Entresto
Location Trials
United States 8
Canada 5
Denmark 3
Ireland 3
Taiwan 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for Entresto
Location Trials
Ohio 2
Minnesota 2
Connecticut 1
Pennsylvania 1
Tennessee 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Entresto

Clinical Trial Phase

Clinical Trial Phase for Entresto
Clinical Trial Phase Trials
Phase 4 16
Phase 3 2
Phase 2 9
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Entresto
Clinical Trial Phase Trials
Recruiting 16
Not yet recruiting 15
Active, not recruiting 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Entresto

Sponsor Name

Sponsor Name for Entresto
Sponsor Trials
Novartis Pharmaceuticals 3
Vanderbilt University Medical Center 3
The Heartbeat Trust 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Entresto
Sponsor Trials
Other 51
Industry 8
NIH 3
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Baxter
Medtronic
Harvard Business School
Mallinckrodt
AstraZeneca
Colorcon

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.